Could Russian Scientist, Mikhail Blagosklonny Have A Breakthrough For Cancer?

Russian scientist, professor, and oncologist, Mikhail Blagosklonny, says what doctors have longed looked into may be possible with the drug Rapaymycin. It’s currently used as a prevention to organ rejection, but it’s also one of five drugs now known to prolong the lifespan of mice “We are sitting on something big,” says Blagosklonny.

It has been used for years as an immunosuppressive cocktail that prevents the rejection of transplanted organs, and has extended the lifespan of certain species such as fruit flies, worms and mice. It’s still unclear just how Rapaymycin works to extend life, but scientists worldwide are studying and testing the effects on more animals. In 2014, studies further showed that the drug enhanced the immune systems of humans, and then scientists began to researching how this could slow down the aging process. Read more about Mikhail on Crunchbase.

Rapamycin have been classified as a mTOR inhibitor. Researchers have proven that this drug counteracts aging and age-related diseases in mice and other animals. Oncologist, Mikhail Blagosklonny says this drug can also counteract aging in humans. “Studies must be carried futher so we can know all the ways Rapamycin can help us eliminate diseases.”

MTOR is an enzyme important for survival, growth, how cells behave, and the proliferation of new healthy cells. However, as mTOR slows down, and stops regulating several processes, the body becomes vulnerable to many chronic diseases. But Rapamycin reverses this natural decline in people as they age, and Blagosklonny believes this is one of the most important fountain-of-youth drugs. View Mikhail’s profile on Google Scholar.

Blagosklonny Looks Toward The Future

Last year this time, Research oncologist, Dr. Mikhail Blagosklonny explained his goals for the future. He’s focusing his research on the best methods to eliminate cancer cells while still protecting normal cells. He says Rapaymycin is not only a cost effective method of possibly eliminating cancer, but it could help with other chronic diseases.

Mikhail Blagosklonny earned his M.D. and Ph.D. at Russia’s First Pavlov State Medical University of St. Petersburg. He moved to New York where he was appointed Associate Professor at New York Medical College. In 2002, he became a senior scientist at Albany’s Ordway Research Institute, and in 2009, a research professor at Roswell Park Cancer Institute. Besides serving as a researcher and investigator of how cancer and aging are interrelated, Mikhail Blagosklonny has also been published in journals and serves as editor-in-chief of several publications, including Aging, Cell Cycle, and Oncotarget. He’s active in a variety of professional organizations and current research projects.


Clay Siegall Aims To Revolutionize The Cancer Treatment Industry


With the advancement of scientific research, more and more companies are choosing to invest in numerous medical fields, especially cancer research. One such company that has been making a significant contribution to the world of cancer research is Seattle Genetics, led by Clay Siegall. The company is geared towards the development of new research and new cancer treatments, with an aim to eventually find out more substantial knowledge on how to prevent and treat this disease which claims millions of lives every year.

Clay Siegall is the man behind Seattle Genetics and the person responsible for the success of the company. Over the past three years, under his leadership, Seattle Genetics has had their stock go up almost threefold.

Clay’s passion for leading Seattle Genetics and developing a right course of treatment for the disease is because Clay’s main aim in life is to ultimately help people and ease the pain they might face as a result of cancer. Clay strives to help as many people as he can through Seattle Genetics and ultimately help revolutionise the course of treatment for cancer. His commitment to transforming the cancer treatment industry has led Seattle Genetics to develop some of the most advanced and cutting edge technology which can be implemented for the treatment of one of the world’s most deadly diseases.

His tremendous commitment and drive to help people surfaces in the numerous endeavors Clay has undertaken under the cap of Seattle Genetics. In the past, Clay has personally raised over $1.2 billion towards cancer research and development of effective treatments. He has been praised by numerous organizations and media outlets for his dedication and contribution to the field of medical research. He has received numerous awards for this effort, such as the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. Also, he has received numerous awards for his leadership, including the Pacific Northwest Ernst & Young Entrepreneur of the Year award. Combining his love for scientific research and his exceptional leadership skills, Clay has managed to propel Seattle Genetics forward in a favorable direction.